First, and most importantly, our base business continues to perform well with strong 5% growth across the base portfolio.
We estimate this accounted for approximately $25 million of the Q1 sales increase over the prior year.
Meanwhile, our financial profile has remained solid throughout the change in consumer purchasing patterns, and we generated record earnings per share of $1.14 and free cash flow of approximately $68 million in Q1.
Combined, these brands represent about 20% of our revenues.
When combined with our existing eye care business, we now have a $100 million-plus franchise that addresses a range of consumer ailments across the $1 billion category.
A brand we've owned since our IPO over 15 years ago, Clear Eyes is an example of how we think about long-term brand-building.
Today, we have over 11 different solutions for consumers solving eye redness.
Q1 revenue of $269.2 million increased 17.3% and 15.6% on an organic basis versus the prior year, the latter excluding the effect of foreign currency.
North America revenues were up about 15%.
International OTC increased approximately 30% in Q1 after excluding the effects of foreign currency.
EBITDA increased in Q1, approximately 13% while EBITDA margin remained consistent with our long-term expectations in the mid-30s.
Diluted earnings per share for the quarter was a record $1.14 per share, up over 30% versus the prior year driven by both the higher sales discussed and lower interest expense.
Q1 fiscal '22 revenues increased 17% versus the prior year.
Our strong and diverse portfolio experienced approximately 5% baseline growth driven by the favorable year ago comparison and our long-term brand-building efforts.
In addition, we experienced a sharp rebound in certain COVID-impacted categories, adding an estimated $25 million to our Q1 revenue performance.
Total company gross margin of 59.1% in the first quarter increased 70 basis points versus last year's gross margin of 58.4%.
We continue to anticipate a gross margin of about 58% for fiscal '22.
Advertising and marketing came in at 14.7% for the first fiscal quarter.
Following the abnormally low rate of spend in Q1 of last year due to COVID-19 shelter-in-place restrictions, A&M returned to normalized levels of spend of approximately 14% to 16%.
For fiscal '22, we still anticipate an approximate 15% A&M rate as a percentage of sales.
And for Q2, we anticipate A&M of closer to 14%.
G&A expenses were just over 8% of sales in Q1.
For the full year fiscal '22, we still anticipate G&A expenses to approximate just over 9% of sales.
Lastly, record diluted earnings per share of $1.14 grew 32.5% over the prior year.
Looking forward, we now anticipate interest for the full year to approximate $63 million, reflecting the recent financing completed in conjunction with the TheraTears acquisition.
In Q1, we generated $67.8 million in free cash flow, down versus the prior year due entirely to the timing of working capital.
At June 30, our net debt was approximately $1.4 billion, inclusive of the cash we built ahead of the anticipated acquisition closing on July 1.
Following the acquisition of Akorn, our net debt at July one was approximately $1.6 billion.
Our covenant-defined leverage ratio was 4.3 times at the closing of the transaction, and we anticipate leverage of approximately four times by year-end fiscal '22.
For the full year fiscal '22, we now anticipate revenues of $1.045 billion or more, which includes an organic revenue growth expectation of about 6% and the revenue from the acquisition of the Akorn Consumer Health.
For the second quarter, we anticipate revenues of $260 million or more.
This revenue outlook assumes a few key factors: one, that the travel-impacted portion of our business will continue at the recovered levels for the remainder of the year; two, we still anticipate flat sales to prior year in the cough and cold and head lice areas of our business; and three, the acquisition of the Akorn portfolio discussed today should contribute approximately $40 million to the fiscal year net sales.
We anticipate adjusted earnings per share of $3.90 or more for fiscal '22.
For Q2, adjusted earnings per share is expected to be $0.95 or more.
These attributes translate into strong free cash flow as well, where we anticipate adjusted free cash flow of $245 million or more for the year.

Summary:
Meanwhile, our financial profile has remained solid throughout the change in consumer purchasing patterns, and we generated record earnings per share of $1.14 and free cash flow of approximately $68 million in Q1.
Q1 revenue of $269.2 million increased 17.3% and 15.6% on an organic basis versus the prior year, the latter excluding the effect of foreign currency.
Diluted earnings per share for the quarter was a record $1.14 per share, up over 30% versus the prior year driven by both the higher sales discussed and lower interest expense.
Lastly, record diluted earnings per share of $1.14 grew 32.5% over the prior year.
Looking forward, we now anticipate interest for the full year to approximate $63 million, reflecting the recent financing completed in conjunction with the TheraTears acquisition.
We anticipate adjusted earnings per share of $3.90 or more for fiscal '22.